REG - JPMorgan Sec.Plc Takeda Pharma.Co.Ltd - Form 8.5 (EPT/RI)- Takeda Pharmaceutical Co Ltd

Takeda Pharmaceutical CoAnnouncement

19/11/2018 11:15

RNS Number : 7740H
JPMorgan Securities Plc
19 November 2018
 


FORM 8.5 (EPT/RI)
 
PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the "Code")
 
1.         KEY INFORMATION
 



(a) Name of exempt principal trader:


J.P. Morgan Securities Plc




(b) Name of offeror/offeree in relation to whose relevant securities this form relates:
     Use a separate form for each offeror/offeree


Takeda Pharmaceutical Company Limited




(c) Name of the party to the offer with which exempt principal trader is connected:


Joint Financial Adviser to Takeda Pharmaceutical Company Limited




(d) Date dealing undertaken:


16 November 2018




(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?
     If it is a cash offer or possible cash offer, state "N/A"


Yes, Shire plc
 



 
2.         DEALINGS BY THE EXEMPT PRINCIPAL TRADER
 
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
 
The currency of all prices and other monetary amounts should be stated.
 
(a)        Purchases and sales
 



Class of relevant security


Purchases/ sales
 


Total number of securities


Highest price per unit paid/received
(JPY)


Lowest price per unit paid/received
(JPY)




Ordinary Shares
 


Purchases
 
Sales


637,519
 
635,719


4,357.0000
 
4,357.0000


4,293.0000
 
4,293.0000



 
(b)        Cash-settled derivative transactions
 



Class of relevant security


Product description
e.g. CFD


Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position


Number of reference securities


Price per unit
 
 
 




Ordinary Shares
 


Equity Swaps


Long
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Short


425,200
425,200
4,531
54,900
100
1,200
400
400
3,700
600
15,500
1,900
100
300
12,300
100
8,300
400
4,900
200
71,000
400
500
400
300
1,200
3,500
1,100
600
9,300
100
200
300
 
425,200
54,700
100
91,200
14,800
200
3,000
3,000
8,400
5,300
34,200
13,000
11,400
4,531
176,300
200
31,900
7,900
19,400
600
100
1,100
123,500
19,000
100


37.8906 USD
38.0310 USD
38.0394 USD
4,293.0000 JPY
4,293.4200 JPY
4,298.4167 JPY
4,300.2500 JPY
4,300.4500 JPY
4,301.0000 JPY
4,302.0000 JPY
4,303.1504 JPY
4,304.6842 JPY
4,305.0000 JPY
4,305.6000 JPY
4,306.6016 JPY
4,308.9000 JPY
4,309.8313 JPY
4,311.0000 JPY
4,311.4286 JPY
4,312.0688 JPY
4,312.2003 JPY
4,314.1750 JPY
4,314.9000 JPY
4,320.7000 JPY
4,322.5667 JPY
4,322.8333 JPY
4,323.9714 JPY
4,324.2273 JPY
4,324.2500 JPY
4,324.3979 JPY
4,329.9000 JPY
4,330.1319 JPY
4,332.0000 JPY
 
37.8906 USD
4,293.0000 JPY
4,293.4293 JPY
4,296.5011 JPY
4,296.7432 JPY
4,299.2365 JPY
4,299.3333 JPY
4,302.1333 JPY
4,302.5476 JPY
4,304.9057 JPY
4,304.9240 JPY
4,306.8137 JPY
4,307.9976 JPY
4,309.8624 JPY
4,312.0528 JPY
4,312.0700 JPY
4,314.0502 JPY
4,317.5222 JPY
4,317.6963 JPY
4,318.9319 JPY
4,322.0000 JPY
4,324.2727 JPY
4,324.7336 JPY
4,325.1842 JPY
4,339.0000 JPY



 
(c)        Stock-settled derivative transactions (including options)
 
(i)         Writing, selling, purchasing or varying
 



Class of relevant security


Product description e.g. call option


Writing, purchasing, selling, varying etc.


Number of securities to which option relates


Exercise price per unit
 


Type
e.g. American, European etc.


Expiry date


Option money paid/ received per unit
 





































 
(ii)        Exercise
 



Class of relevant security


Product description
e.g. call option


Exercising/ exercised against


Number of securities


Exercise price per unit
 




















 
 



 
(d)        Other dealings (including subscribing for new securities)
 



Class of relevant security


Nature of dealing
e.g. subscription, conversion


Details


Price per unit (if applicable)








 
 











 
3.         OTHER INFORMATION
 
(a)        Indemnity and other dealing arrangements
 



Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included.  If there are no such agreements, arrangements or understandings, state "none"




None
 
 



 
(b)        Agreements, arrangements or understandings relating to options or derivatives
 



Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i)  the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"




None
 



 
 



Date of disclosure:


19 November 2018




Contact name:


Alwyn Basch




Telephone number:


020 7742 7407



 
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.
 
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FERFFUFFUFASESF